Clinical TrialJun 8, 2026, 04:06 PM
Century Therapeutics CNTY-813 Preclinical Data Positive; IND on Track
AI Summary
Century Therapeutics announced positive new preclinical data for CNTY-813, its iPSC-derived islet replacement therapy for Type 1 Diabetes, at the American Diabetes Association 86th Scientific Sessions. The data showed durable glucose control for over eight months in preclinical models and confirmed the efficacy of its Allo-Evasion™ 5.0 technology in maintaining normoglycemia without immunosuppression. The company has also established its Phase 1 clinical manufacturing process and remains on track for an IND submission in 4Q 2026, with initial clinical data expected in 2H 2027.
Key Highlights
- CNTY-813 demonstrated durable glucose control for over eight months in preclinical models.
- Allo-Evasion™ 5.0 maintained insulin secretion and normoglycemia under allogeneic immune pressure without immunosuppression.
- Phase 1 clinical manufacturing process for CNTY-813 has been established, showing consistent endocrine purity.
- Investigational New Drug (IND) submission for CNTY-813 is on track for 4Q 2026.
- Initial clinical data from the first-in-human CNTY-813 study is anticipated in 2H 2027.
- No tumorigenesis was observed in over 140 mice with more than three months of follow-up.
- CNTY-813 contains an optimal ratio of differentiated cell types, with beta cells comprising over 50% of total cell composition.
Price Impact
More from IPSC